IFNG and metabolic syndrome: Expression and/or activity of eNOS substantially decreases in response to classic atherogenic culprits such as chronic inflammation (TNF, interleukin 1, and IFNγ), oxidative stress, hypoxia, hyperglycemia, and dyslipidemias (45–48).